Management meeting highlights 2026-27 clinical catalysts for Sana’s SC451 and SG293 programs

Overview

This management-meeting note focuses on Sana Biotechnology’s two lead cell-therapy programs and the clinical milestones expected to shape its outlook through 2027. Goldman Sachs identifies SC451 study initiation and early human data for both SC451 and SG293 as the principal prospective value catalysts.

Core views

Goldman Sachs’ discussion with Sana management centered on SC451, a stem-cell-derived pancreatic islet-cell therapy for type 1 diabetes that uses Sana’s hypoimmune (HIP) modifications. The company plans clinical transition in 2026 after completing remaining IND activities, including GMP manufacturing technology transfer; management said most other IND-enabling work, including non-clinical testing and GLP toxicology studies, has been completed. An early marker of success would be evidence of SC451 cell survival around one month after implantation, which management expects may be disclosed by press release. The report frames the UP421 investigator-sponsored trial as supporting evidence for SC451. UP421 uses cadaveric islet cells, while SC451 uses iPSC-derived islet cells, but both employ the same HIP modifications: HLA I/II deletion and CD47 overexpression. Management cited 14-month UP421 data showing transplanted-cell survival and function without immunosuppression, including circulating C-peptide as evidence that transplanted beta cells were producing insulin, with no safety signals reported. Management believes these findings support the likelihood of durable HIP-modified cell survival and reduce, though do not eliminate, perceived immune-rejection risk. Sana is also prioritizing manufacturing scale-up for a potential registrational study and future launch, while saying it has sufficient capacity for initial clinical testing. The company highlighted an approximately 10 million global type 1 diabetes patient population growing about 5% annually. For SG293, Sana’s CD19-targeted in vivo CAR-T program, initial lymphoma data from an investigator-initiated trial in China are now expected in 1H27, versus prior expectations for 2026. Management attributed the delay to trial-site initiation complexity, while noting a backup site and efforts to start studies in an additional geography outside China. Sana argues that its paramyxovirus-based fusosome platform may provide differentiated safety and specificity because it uses CD8 targeting for T-cell entry, rather than the CD3 approach used by certain competitors, potentially limiting initial T-cell activation. This argument follows recent competitor safety findings involving an IEC-HS-like syndrome. Management also sees possible expansion into autoimmune disease and said its BCMA-targeted in vivo CAR-T candidate SG227 could enter the clinic after platform validation from initial SG293 results. On capital allocation, management described a tactical approach: it may raise capital after positive clinical proof-of-concept data and is open to partnerships, including for SG293, where it cited pharmaceutical interest in in vivo CAR-T. Goldman Sachs therefore identifies the planned SC451 study start and the initial first-in-human data from both lead programs as the key upcoming value-unlocking events. The valuation materials illustrate the dependence of estimated value on clinical probabilities of success, discount rates and terminal growth assumptions. Goldman Sachs uses base probabilities of success of 25% for SC451 in type 1 diabetes and 15% for SG293 in systemic lupus erythematosus and non-Hodgkin lymphoma. Under the broad WACC/terminal-growth sensitivity, indicated values range from $8 at a 21% discount rate and -2% terminal growth to $38 at an 8% discount rate and 5% terminal growth. The company is designated Early-Stage Biotech, so no investment rating or target price is assigned.

Analysis framework

The report evaluates management’s program timelines, supporting clinical evidence, platform differentiation, manufacturing readiness and financing options. It then illustrates valuation sensitivity to drug-level probabilities of success, the weighted average cost of capital and terminal growth assumptions.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  WACC and terminal-growth-rate sensitivity analysis

  Goldman Sachs varies the discount rate and terminal growth rate to show how valuation changes under different financing and long-term growth assumptions.

• Other

  Drug-program probability-of-success sensitivity analysis

  The valuation assigns explicit clinical probabilities of success to SC451 and SG293 and tests how changes in those assumptions affect estimated value.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sana Biotechnology (SANA)

  Primary subject; the report links prospective value creation to clinical initiation and early data from SC451 and SG293.

  Strengths

  Supporting UP421 data for HIP-modified islet cells; differentiated CD8-targeted fusosome approach for SG293; initial clinical manufacturing capacity.

  Weaknesses

  Lead programs remain in IND-enabling stages and lack first-in-human data.

  Comparison

  Management distinguishes SG293’s CD8-targeted entry mechanism from competitors using CD3 targeting.

  Risks

  Clinical, trial-initiation, manufacturing, safety and financing uncertainty remain material.

Key data

• SC451 clinical transition2026Planned after remaining IND activities and GMP manufacturing technology transfer.
• UP421 supporting data14 monthsManagement cited transplanted-cell survival and function without immunosuppression, with no safety signals.
• SG293 initial lymphoma data1H27Now expected from an investigator-initiated China study, versus prior expectations for 2026.
• Base probability of success25% for SC451 in T1D; 15% for SG293 in SLE and NHLAssumptions used in Goldman Sachs’ valuation sensitivity analysis.
• Valuation sensitivity range$8 to $38Range shown under 21% WACC/-2% terminal growth versus 8% WACC/5% terminal growth.
• Share price$2.92Price as of the 16 Sep 2026 close.

Impact & implications

The report presents clinical execution as the primary determinant of Sana’s near- to medium-term outlook. Evidence of SC451 engraftment and safety, successful SG293 study initiation and early human data could validate the company’s HIP and in vivo CAR-T platforms, while positive data could also broaden financing and partnership options.

Risks

• SC451 still requires completion of remaining IND activities and successful clinical initiation.
• The relevance of UP421 results to SC451 remains subject to the difference between cadaveric and iPSC-derived islet cells.
• SG293’s initial data timing has been delayed by trial-site initiation complexity.
• Recent competitor CAR-T safety findings underscore potential safety risk for the in vivo CAR-T field.
• Future capital raising or partnership execution remains uncertain.

What to watch

• Completion of SC451 IND activities, including GMP manufacturing technology transfer, and planned 2026 study initiation.
• SC451 cell-survival evidence around one month after initial implantation.
• Initial SG293 lymphoma data from the China investigator-initiated trial in 1H27.
• Progress toward SG293 studies outside China and potential autoimmune-disease development.
• Any financing or partnership activity following clinical proof-of-concept data.